A new approach to the inflammatory/autoimmune diseases

Recent Patents on Anti-Infective Drug Discovery

Volumn 4, Issue 2, 2009, Pages 108-113

  Ferrero, Maria E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Autoimmunity; Extracellular ATP; Inflammation; Oxidized ATP (oATP); Pain

Indexed keywords

ADENOSINE TRIPHOSPHATE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; PERIODATE OXIDIZED ADENOSINE TRIPHOSPHATE; PURINERGIC P2X RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; ANALGESIC AGENT; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; DRUG DERIVATIVE; PERIODATE OXIDIZED ADENOSINE 5' TRIPHOSPHATE; PERIODATE-OXIDIZED ADENOSINE 5'-TRIPHOSPHATE; PURINERGIC P2 RECEPTOR; PURINERGIC P2X1 RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CELL ACTIVATION; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DOWN REGULATION; DRUG DETERMINATION; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; MONONUCLEAR CELL; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; BIOLOGICAL MODEL; DRUG ANTAGONISM; EXTRACELLULAR FLUID; IMMUNITY; METABOLISM; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; ANALGESICS; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; EXTRACELLULAR FLUID; HUMANS; IMMUNITY; INFLAMMATION; MODELS, BIOLOGICAL; RECEPTORS, PURINERGIC P2;

EID: 69149102967     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489109788490343     Document Type: Review

References (51)

1. Haag F, Adriouch S, Brab A, et al. Extracellular NAD and ATP: Partners in immune cell modulation. Purinergic Signal 2007; 3: 71-81.
2. Burnstock G. Purinergic nerves. Pharmacol Rev 1972; 24: 509-581.
3. Burnstock G. Do some nerve cells release more than one transmitter? Neuroscience 1976; 1: 239-248.
4. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 2007; 87: 659-797.
5. Maria AP, Burnstock G, Verkhratsky A, Zimmermann H. Purinergic signalling in the nervous system: An overview. Trends Neurosci 2009; 32: 19-29.
6. Burnstock G. Purinergic signalling. Br J Pharmacol 2006; 147 (Suppl 1): S172-181.
7. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-492.
8. Samuel FJ, Burnstock G. An evolutionary history of P2X receptors. Purinergic Signal 2008, in press.
9. Garcia-Marcos M, Dehaye Jean-P, Marino A. Membrane compartments and purinergic signalling: The role of plasma membrane microdomains in the modulation of P2XR-mediated signalling. FEBS J 2009; 276: 330-340.
10. Banfi C, Ferrario S, De Vincenti O, et al. P2 receptors in human heart: Upregulation of P2X6 in patients undergoing heart transplantation, interaction with TNF α and potential role in myocardial cell death. J Mol Cell Cardiol 2005; 39: 929-939.
11. Cattaneo M. Platelet P2 receptors: Old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther 2007; 5: 45-55.
12. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 466-472.
13. Ford APDW, Joel GR, Philip NA, et al. Purino-ceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol 2006; 147 (Suppl 2): S132-143.
14. Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov 2008; 7: 575-590.
15. Donnelly-Roberts D, McGaraughty S, Shieh Char-C, Honore P, Michel JF. Painful purinergic receptors. J Pharmacol Exp Ther 2008; 324: 409-415.
16. Diana D-RL, Michel JF. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol 2007; 151: 571-579.
17. Ana, J.I., Sesto, A., José, R.P., Gascon, I., De Buitrago, Gonzalo, G., Maria, J.C.: US20090005330 (2009).
18. Murgia M, Hanau S, Pizzo P, Rippa M, Di Virgilio F. Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. J Biol Chem 1993; 268: 8199-8203.
19. Kennedy C, Leff P. Painful connection for ATP. Nature 1995; 377: 385-386.
20. Dell'Antonio G, Quattrini A, Dal CE, Fulgenzi A, Maria FE. Antinociceptive effect of a new P(2Z)/P2X7 antagonist, oxidized ATP, in arthritic rats. Neurosci Lett 2002; 327: 87-90.
21. Dell'Antonio G, Quattrini A, Cin ED, Fulgenzi A, Maria FE. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum 2002; 46: 3378-3385.
22. Fulgenzi A, Dell'Antonio G, Foglieni C, et al. Inhibition of chemokine expression in rat inflamed paws by systemic use of the antihyperalgesic oxidized ATP. BMC Immunol 2005; 6: 18-29.
23. Fulgenzi A, Ticozzi P, Christopher GA, et al. Periodate oxidized ATP (oATP) reduces hyperalgesia in mice: Involvement of P2X7 receptors and implications for therapy. Int J Immunopathol Pharmacol 2008; 21: 61-71.
24. Reza BD, Sylvia KB, Aquilina G, George DR. Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor-independent mechanisms. Br J Pharmacol 2003; 140: 507-519.
25. Schenk U, Astrid WM, Radaelli E, et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal 2008; 1: ra6.
26. Olavio BR, Ferrari D, Melchiorri L, et al. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 1996; 87: 682-690.
27. Brough D, Pelegrin P, Nancy RJ. Pannexin-1-dependent caspase-1 activation and secretion of IL-1beta is regulated by zinc. Eur J Immunol 2009; 39: 352-358.
28. Michelle KJ, Kathleen LC, Sylvia KB, Qu Y, George DR. Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-kappaB-driven protein synthesis. J Immunol 2005; 175: 7611-7622.
29. Macian F, Garcia-Cozar F, Im Sin-H, Heidi HF, Michael BC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002; 109: 719-731
30. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008; 455: 808-812.
31. Trautmann A. Extracellular ATP in the immune system: more than just a "danger signal". Sci Signal 2009; 2(56): pe6.
32. Strand V, Kimberly R, John ID. Biologic therapies in rheumatology: Lessons learned, future directions. Nat Rev Drug Discov 2007; 6: 75-92.
33. Caporali F, Capecchi PL, Gamberucci A, et al. Human rheumatoid synoviocytes express functional P2X7 receptors. J Mol Med 2008; 86: 937-949.
34. Szekanecz Z, Alisa KE. Macrophages and their products in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 289-295.
35. Pétrilli V, Dostert C, Daniel MA, Tschopp J. The inflam-masome: A danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19: 615-622
36. Mihai NG, van de Veerdonk Frank L, Bart KJ, Van der Meer Jos WM, Leo JAB. The role of NLRs and TLRs in the activation of the inflammasome. Expert Opin Biol Ther 2008; 8: 1867-1872.
37. Hong YB, Brett FB. The caspase-1 inflammasome: A pilot of innate immune responses. Cell Host Microbe 2008; 4: 198-208.
38. Virgilio DF. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci 2007; 28: 465-472.
39. Piccini A, Carta S, Tassi S, Lasiglie D, Fossati G, Rubartelli A. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1beta and IL-18 secretion in an autocrine way. Proc Natl Acad Sci USA 2008; 105: 8067-8072.
40. Coutinho-Silva R, Corrêa G, Abdul SA, David OM. The P2X(7) receptor and intracellular pathogens: A continuing struggle. Purinergic Signal 2009, in press.
41. Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. Brain Res Rev 2008, in press.
42. Lee Y-R, Kweon S-H, Kwon K-B, Park J-W, Yoon T-R, Park B-H. Inhibition of IL-1beta-mediated inflammatory responses by the IkappaB alpha super-repressor in human fibroblast-like synoviocytes. Biochem Biophys Res Commun 2009; 378: 90-94.
43. Al-Shukaili A, Al-Kaabi J, Hassan B. A comparative study of interleukin-1beta production and p2x7 expression after ATP stimulation by peripheral blood mononuclear cells isolated from rheumatoid arthritis patients and normal healthy controls. Inflammation 2008; 31: 84-90.
44. Matute C, Torre I, Perez-Cerda F, et al. P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci 2007; 27: 9525-9533.
45. Guy, J.: WO2008063802 (2008).
46. Atzeni F, Antivalle M, Francesca PB, et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009; 8: 431-437.
47. Finckh A, Simard JF, Gabay C, Guerne Pierre-A. SCQM physicians Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-752.
48. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-744.
49. Descotes J, Gouraud A. Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 2008; 4: 1537-1549.
50. O'Mahony R, Richards A, Deighton C, Scott D. Withdrawal of DMARDs in patients with Rheumatoid Arthritis: A systematic review and meta-analysis. Ann Rheum Dis 2009, in press.
51. Sandra WJ, Paul RA, Francis KJ, John LC. Pain behavior in rheumatoid arthritis patients: Identification of pain behavior subgroups. J Pain Symptom Manage 2008; 36: 69-78.